Background There is no drug therapy for abdominal aortic aneurysm (AAA). FAME‐2
(Fenofibrate in the Management of Abdominal Aortic Aneurysm 2) was a placebo‐controlled …

Background and aims Abdominal aortic aneurysm (AAA) is an important cause of death
worldwide and has an estimated heritability between 70 and 77%. Genome-wide …

Intraluminal thrombus is a consistent feature of human abdominal aortic aneurysm (AAA).
Coagulation factor Xa (FXa) catalyses FII to thrombin (FIIa). We examined the effect of …

A common feature in patients with abdominal aortic aneurysms (AAAs) is the formation of a
nonocclusive intraluminal thrombus (ILT) in regions of aortic dilation. Platelets are known to …

Abdominal aortic aneurysm (AAA) is associated with high morbidity and mortality and is an
established cause of unbalanced hemostasis. A number of hemostatic biomarkers have …

Background Etiology and risk factors of peripheral artery disease (PAD) include age,
smoking, and hypertension, etc., which are shared by an abdominal aortic aneurysm (AAA) …

Background: Surveillance programs in abdominal aortic aneurysms (AAA) are mainly based
on imaging and leave room for improvement to timely identify patients at risk for AAA growth …

Abdominal aortic aneurysm (AAA) is a common age-related vascular disease characterized
by progressive weakening and dilatation of the aortic wall. Thrombospondin-1 (TSP-1; gene …

Since aortic aneurysms (AAs) are mostly asymptomatic, but they have a high mortality rate
upon rupture, their detection and progression evaluation are clinically important issues. To …

OBJECTIVE: Abdominal aortic aneurysm (AAA) is usually accompanied by the formation of a
large volume of intra-luminal thrombus (ILT). ILT-derived proteins have been suggested as …